Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
Xianmeng Chen(University of Science and Technology of China), Xiaowen Hu(Lanzhou University), Xuqin Jiang(University of Science and Technology of China), Daqing Xia(University of Science and Technology of China), Jay H. Ryu(Mayo Clinic), Lejie Cao(University of Science and Technology of China)
Cited by 3
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
The NHLBI Lymphangioleiomyomatosis Registry
|American Journal of Respiratory and Critical Care Medicine|2005|479
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management
|American Journal of Respiratory and Critical Care Medicine|2016|366